Publicly disclosed partnering transactions per Burrill & Co.

Burrill & Co. issues quarterly publications, which includes information on collaborations during the period, based on size.
At the time of posting, Q4 05 is not available. The third quarter of 2004 (most of the referenced agreements became available in '05) and the first three quarters of 2005 are set out below:

From Burrill's Selected Partnering Transactions during Q4 04:

Companies	(USD$M)	Publicly Available:
Medarex/Bristol Myers Squibb	$530	Yes
Plexxikon/Wyeth	$372	No
Nastech/Merck	$341	Yes
Pharmasset/Roche	$300	No
CancerVax/Serono	$278	Yes
Sucampo /Takeda	$210	No
HGS/GlaxoSmithKline	$183	No
Micromet/Serono	$138	No
Zilip-Pharma/Bayer	$100	No
ZymoGenetics/Novo Nordisk	$ 77	Yes

From Burrill's Selected Partnering Transactions during Q1 05:

Biotech/Pharma	Est. Value (US$M)	Publicly Available:
Coley/Pfizer	505	Yes
New River/Shire	500	Yes
Basilea/Cilag (A Johnson & Johnson company)	312	No
Theravance/GlaxoSmithKline	252	Yes
Gilead/Japan Tobacco	105	Yes
Acadia/Sepracor	95	Yes
Andrx/First Horizon	85	Yes
Xenova/Oxxon Therapeutics	82	Yes
Vertex/Avalon Pharmaceuticals	73	Yes
Neose/BioGeneriX	62	Yes

From Burrill's Selected Partnering Transactions during Q2 05:

Biotech Pharma/Biotech	Est. Value (US$M)	Publicly Available:
Talecris/Bayer	650	Yes
Anadys /Novartis	570	Yes
Arakis -Vectura/Novartis	346	No
BioMarin/Serono	257	Not Yet
Arrow/Novartis	227	No
Lexicon/Organon (Akzo Nobel)	223	Yes
Avanir/Novartis	210	Yes
Renovis/Pfizer	187	Yes
BioXell/Merck	150	No
Hybridon /Novartis	136	Yes
NovImmune/Serono	116	No

From Burrill's Selected Partnering Transactions during Q3 05:

Biotech/Pharma	(US$M)	Publicly Available:
PDL/Biogen	800	Yes
Alnylam/Novartis	700	Yes
Avanir/AstraZeneca	340	Yes
Sirna/Allergan	250	Yes
Astex/AstraZeneca	275	No
GenMab/Serono	215	No

Technorati tag: Biotech licensing